EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis

Kaviyon Sadrolashrafi, Lily Guo, Robin Kikuchi, Audrey Hao iD, Rebecca K Yamamoto, Hannah C Tolson, Sara N Bilimoria, Danielle K Yee, April W Armstrong

Cells · 28.03.2024 · 13 (7) · 587

DOI: 10.3390/cells13070587 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 28.03.2024. Verfasst von Kaviyon Sadrolashrafi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transmembrane glycoprotein OX40 receptor (OX40) and its ligand, OX40L, are instrumental modulators of the adaptive immune response in humans. OX40 functions as a costimulatory molecule that promotes T cell activation, differentiation, and survival through ligation with OX40L. T cells play an integral role in the pathogenesis of several inflammatory skin conditions, including atopic dermatitis (AD). In particular, T helper 2 (TH2) cells strongly contribute to AD pathogenesis via the production of cytokines associated with type 2 inflammation (e.g., IL-4, IL-5, IL-13, and IL-31) that lead to skin barrier dysfunction and pruritus. The OX40-OX40L interaction also promotes the activation and proliferation of other T helper cell populations (e.g., TH1, TH22, and TH17), and AD patients have demonstrated higher levels of OX40 expression on peripheral blood mononuclear cells than healthy controls. As such, the OX40-OX40L pathway is a potential target for AD treatment. Novel therapies targeting the OX40 pathway are currently in development, several of which have demonstrated promising safety and efficacy results in patients with moderate-to-severe AD. Herein, we review the function of OX40 and the OX40-OX40L signaling pathway, their role in AD pathogenesis, and emerging therapies targeting OX40-OX40L that may offer insights into the future of AD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansCell DifferentiationCytokinesInflammationLeukocytes, MononuclearOX40 LigandReceptors, OX40

Stichwörter der Autor:innen

ADAD pathogenesisOX40OX40LT cellsatopic dermatitiscytokineseczemainflammationmonoclonal antibodies

Substanzen

CytokinesTNFSF4 protein, humanOX40 LigandTNFRSF4 protein, humanReceptors, OX40

Autor:innen und Institutionen

  • Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

ORCID-Profile: Audrey Hao

Zitieren

APA

Sadrolashrafi, K., Guo, L., Kikuchi, R., Hao, A., Yamamoto, R. K., Tolson, H. C., Bilimoria, S. N., Yee, D. K., & Armstrong, A. W. (2024). An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis. Cells, 13(7), 587. https://doi.org/10.3390/cells13070587

Vancouver

Sadrolashrafi K, Guo L, Kikuchi R, Hao A, Yamamoto RK, Tolson HC, et al. An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis. Cells. 2024;13(7):587. doi:10.3390/cells13070587

BibTeX
@article{Sadrolashrafi2024,
  author = {Sadrolashrafi, Kaviyon and Guo, Lily and Kikuchi, Robin and Hao, Audrey and Yamamoto, Rebecca K and Tolson, Hannah C and Bilimoria, Sara N and Yee, Danielle K and Armstrong, April W},
  title = {An OX-Tra’Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {587},
  doi = {10.3390/cells13070587}
}
Kostenlos starten →